News: CorMedix to join Russell 3000 Index $CRMD

CorMedix Inc., a bio pharmaceutical company focused on treatment of cardiac, renal and infectious disease, is proud to be a part of Russell 3000 Indexes family.

Randy Milby, CorMedix Chief Executive Officer says, “Inclusion in the Russell 3000 and Global Index is a significant milestone for the Company as we continue to execute on our growth strategy and advance Neutrolin.

View the full release here.